Adjuvant therapy with pembrolizumab in renal cell carcinoma: real-world experiences from a retrospective, multi-institutional cohort.

Introduction: Adjuvant pembrolizumab versus placebo significantly improved disease-free survival (DFS) in renal cell carcinoma (RCC) patients at high risk of recurrence following nephrectomy in KEYNOTE-564 trial (NCT03142334). The objective of this study was to evaluate efficacy and safety of adjuvant pembrolizumab in a real-world setting.

Methods: In this multicenter retrospective study, RCC patients receiving adjuvant pembrolizumab between 01/22 and 10/23 at seven tertiary referral centers were included.

An analysis of renal and surgical outcomes of patients with and without preoperative ureteral stenting before Nephron-Sparing Surgery for renal malignancies of higher complexity by using a propensity score-based approach.

Introduction: This study aims to evaluate the impact of preoperative ureteral stenting on postoperative outcomes, especially the incidence of urinoma, in patients with complex renal tumors undergoing nephron-sparing surgery.

Methods: A retrospective analysis of 35 patients who received preoperative ureteral stenting prior to nephron-sparing surgery for complex tumors at the University Hospital of Würzburg between 2002 and 2021. A control group of 115 patients was established through 1:3 propensity score matching based on age, gender, T-stage, and RENAL score.

Evaluation of cyclin-dependent kinase 4/6 inhibitor-induced serum creatinine elevations in patients with hormone receptor positive breast cancer.

Background: Cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) have improved the efficacy of endocrine therapy in hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) breast cancer (BC) and are now used in both early-stage and metastatic disease. Recent case reports suggest that pseudo-serum creatinine (Scr) elevations are likely a class effect of CDK4/6i.

Methods: This single-center retrospective analysis included patients aged ≥18 years who received at least one dose of palbociclib, ribociclib, or abemaciclib for the treatment of HR+/HER2- BC in the early or advanced setting.

Efficient cryogenic orange Pr:YLF lasers.

We present experimental evidence that the efficiency of orange Pr lasers is limited by losses due to ground state absorption. To this end, we determined the temperature-dependent orange reabsorption and performed laser experiments with orange Pr:YLF lasers at 604 nm and 607 nm in the temperature range between 78 K and 295 K. At 110 K, a slope efficiency of 67% and an optical-to-optical efficiency of 64% are obtained.